Scholarlink

Background <p>The C-reactive protein-to-albumin ratio (CAR) reflects systemic inflammation and malnutrition, but its association with survival in anlotinib-treated advanced non-small cell lung cancer (NSCLC) remains unexplored.</p> Methods <p>We retrospectively analyzed 417 patients with stage IIIB-IV NSCLC treated with anlotinib at Zhongshan Hospital, Fudan University and Zhongshan Hospital (Xiamen), Fudan University. Baseline CAR was calculated as serum C-reactive protein (mg/L) divided by albumin (g/L). Overall survival (OS) was defined as the time from treatment initiation to death or last follow-up. Cox proportional hazards models, restricted cubic spline (RCS) analysis, and two-piecewise linear regression model were applied to evaluate the association between CAR and OS. Subgroup analyses were further performed for robustness.</p> Results <p>Among 417 patients (mean age 62.2 ± 10.33&#xa0;years), 216 deaths (51.8%) occurred during follow-up. The median CAR was 0.34 (0.08–1.09). In multivariable Cox models, elevated CAR was independently associated with worse OS (HR 1.10, 95% CI 1.01–1.21, <i>p</i> = 0.031). RCS analysis revealed a nonlinear association between CAR and OS (<i>p</i> for nonlinearity &lt; 0.001). The inflection point was 2.12: below this threshold, higher CAR significantly increased mortality risk (HR 1.92, 95% CI 1.54–2.40, <i>p</i> &lt; 0.0001), whereas above 2.12, CAR showed a non-significant trend toward lower risk (HR 0.82, 95% CI 0.68–1.00, <i>p</i> = 0.050). Subgroup analyses demonstrated consistent associations across most clinical strata.</p> Conclusion <p>Baseline CAR is a strong and independent prognostic marker for OS in advanced NSCLC patients treated with anlotinib. Its simplicity and availability make it a valuable tool for clinical risk stratification and treatment planning.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Jiaxin Liu,
  • Jinzhan Chen,
  • Jianying Liu,
  • Xiong Xiao,
  • Haiyan Chen,
  • Yijiao Xu,
  • Zhisheng Chen,
  • Hongni Jiang,
  • Lin Tong,
  • Congyi Xie

摘要

Background

The C-reactive protein-to-albumin ratio (CAR) reflects systemic inflammation and malnutrition, but its association with survival in anlotinib-treated advanced non-small cell lung cancer (NSCLC) remains unexplored.

Methods

We retrospectively analyzed 417 patients with stage IIIB-IV NSCLC treated with anlotinib at Zhongshan Hospital, Fudan University and Zhongshan Hospital (Xiamen), Fudan University. Baseline CAR was calculated as serum C-reactive protein (mg/L) divided by albumin (g/L). Overall survival (OS) was defined as the time from treatment initiation to death or last follow-up. Cox proportional hazards models, restricted cubic spline (RCS) analysis, and two-piecewise linear regression model were applied to evaluate the association between CAR and OS. Subgroup analyses were further performed for robustness.

Results

Among 417 patients (mean age 62.2 ± 10.33 years), 216 deaths (51.8%) occurred during follow-up. The median CAR was 0.34 (0.08–1.09). In multivariable Cox models, elevated CAR was independently associated with worse OS (HR 1.10, 95% CI 1.01–1.21, p = 0.031). RCS analysis revealed a nonlinear association between CAR and OS (p for nonlinearity < 0.001). The inflection point was 2.12: below this threshold, higher CAR significantly increased mortality risk (HR 1.92, 95% CI 1.54–2.40, p < 0.0001), whereas above 2.12, CAR showed a non-significant trend toward lower risk (HR 0.82, 95% CI 0.68–1.00, p = 0.050). Subgroup analyses demonstrated consistent associations across most clinical strata.

Conclusion

Baseline CAR is a strong and independent prognostic marker for OS in advanced NSCLC patients treated with anlotinib. Its simplicity and availability make it a valuable tool for clinical risk stratification and treatment planning.